Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Director | June 10, 2026 | June 12, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,168 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 14,083 · Balance 44,168 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 14,083 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,656 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 13,656 · Balance 13,656 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. |
| Stock Option (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2036-06-10 | Direct | 6,209 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 6,209 · Balance 6,209 F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date.
F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.
REPLIGEN CORP
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,062 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Tax withholding · Disposed 9,897 · Balance 89,062 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 15,046 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,017 | $276.20 | $1,109,495.40 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,462 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F4 · price: $276.20 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.54 to $276.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,955 | $274.83 | $537,292.65 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,479 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F3 · price: $274.83 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.43 to $275.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,061 | $273.91 | $564,528.51 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,434 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F2 · price: $273.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.40 to $274.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:45 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 10,000 | $32.40 | $324,000.00 |
DisclosureSEC source: 0000899243-21-045407 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.40 | $0.00 |
DisclosureSEC source: 0000899243-21-035722 · doc4.xml · derivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,154 Underlying: Common Stock · 25,000 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 8 | $296.58 | $2,372.64 |
DisclosureSEC source: 0000899243-21-035722 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,495 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,631 | $296.09 | $482,922.79 |
DisclosureSEC source: 0000899243-21-035722 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,503 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F4 · price: $296.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $295.49 to $296.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 14,825 | $294.90 | $4,371,892.50 |
DisclosureSEC source: 0000899243-21-035722 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,134 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F3 · price: $294.90 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $294.49 to $295.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 8,536 | $294.22 | $2,511,461.92 |
DisclosureSEC source: 0000899243-21-035722 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,959 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F2 · price: $294.22 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.49 to $294.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:24 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 25,000 | $32.40 | $810,000.00 |
DisclosureSEC source: 0000899243-21-035722 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 20:16 UTC | REPLIGEN CORP RGEN · Entity 486 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033450 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,495 F1 · kind: The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 380 | $175.15 | $66,557.00 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 8 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,495 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F9 · price: $175.15 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.98 to $175.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,819 | $174.41 | $491,661.79 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,875 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F8 · price: $174.41 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,560 | $173.19 | $270,176.40 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,694 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F7 · price: $173.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.96 to $173.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,036 | $172.52 | $523,770.72 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,254 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F6 · price: $172.52 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.96 to $172.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,420 | $171.32 | $585,914.40 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,290 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F5 · price: $171.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.93 to $171.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 7,911 | $170.28 | $1,347,085.08 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,710 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F4 · price: $170.28 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.91 to $170.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,529 | $169.45 | $428,539.05 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,621 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F3 · price: $169.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.90 to $169.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2021 Filed May 21, 2021 01:00 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 612 | $168.29 | $102,993.48 |
DisclosureSEC source: 0000899243-21-020294 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,150 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F2 · price: $168.29 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.61 to $168.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 13, 2021 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 235 | $194.08 | $45,608.80 |
DisclosureSEC source: 0000899243-21-011408 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,762 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F8 · price: $194.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.92 to $194.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 13, 2021 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 227 | $193.30 | $43,879.10 |
DisclosureSEC source: 0000899243-21-011408 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,997 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F7 · price: $193.30 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.78 to $193.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 13, 2021 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,378 | $192.17 | $264,810.26 |
DisclosureSEC source: 0000899243-21-011408 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,224 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F6 · price: $192.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.67 to $192.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 13, 2021 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,081 | $191.19 | $206,676.39 |
DisclosureSEC source: 0000899243-21-011408 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,602 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F5 · price: $191.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.64 to $191.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 13, 2021 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,096 | $190.17 | $778,936.32 |
DisclosureSEC source: 0000899243-21-011408 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,683 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F4 · price: $190.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.59 to $190.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 13, 2021 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,171 | $188.77 | $221,049.67 |
DisclosureSEC source: 0000899243-21-011408 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,779 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F3 · price: $188.77 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.55 to $189.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 13, 2021 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 914 | $188.06 | $171,886.84 |
DisclosureSEC source: 0000899243-21-011408 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,950 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2020. F2 · price: $188.06 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.53 to $188.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,633 | $185.22 | $302,464.26 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 9 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,864 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F9 · price: $185.22 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.43 to $185.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,746 | $185.91 | $882,328.86 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 8 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,497 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F8 · price: $185.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.45 to $186.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,271 | $186.90 | $798,249.90 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,243 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F7 · price: $186.90 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.47 to $187.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 595 | $187.48 | $111,550.60 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,514 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,193 | $193.45 | $1,198,035.85 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,109 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F6 · price: $193.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.00 to $193.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,125 | $194.43 | $413,163.75 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,302 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F5 · price: $194.43 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.03 to $194.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,082 | $195.54 | $211,574.28 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,427 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F4 · price: $195.54 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.06 to $195.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 461 | $196.44 | $90,558.84 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,509 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F3 · price: $196.44 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.38 to $196.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:51 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 794 | $197.94 | $157,164.36 |
DisclosureSEC source: 0000899243-21-010560 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,970 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F2 · price: $197.94 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.81 to $198.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:04 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 12,601 | $0.00 Strike: $215.58 | $0.00 |
DisclosureSEC source: 0000899243-21-008460 · doc4.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,601 Underlying: Common Stock · 12,601 shares Expires 2031-02-24 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 24, 2022, February 24, 2023 and February 24, 2024. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:04 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 10,437 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008460 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,764 F1 · shares: Mr. Hunt was awarded 10,437 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 00:03 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $26.05 | $0.00 |
DisclosureSEC source: 0000899243-20-031964 · doc4.xml · derivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 00:03 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,430 | $187.60 | $268,268.00 |
DisclosureSEC source: 0000899243-20-031964 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,327 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F5 · price: $187.60 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.19 to $189.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 00:03 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,300 | $186.50 | $1,174,950.00 |
DisclosureSEC source: 0000899243-20-031964 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,757 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F4 · price: $186.50 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.12 to $187.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 00:03 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,823 | $185.67 | $1,266,826.41 |
DisclosureSEC source: 0000899243-20-031964 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,057 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F3 · price: $185.67 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.12 to $186.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 00:03 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 5,447 | $184.69 | $1,006,006.43 |
DisclosureSEC source: 0000899243-20-031964 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,880 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F2 · price: $184.69 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.11 to $185.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 19, 2020 Filed Nov 24, 2020 00:03 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 20,000 | $26.05 | $521,000.00 |
DisclosureSEC source: 0000899243-20-031964 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Feb 10, 2021 21:01 UTC | REPLIGEN CORP RGEN · Entity 486 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005643 · doc5.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,327 F1 · kind: Represents shares of Common Stock that the reporting person donated as a gift to the Hunt Family Fund, a donor advised fund. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 11:43 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,351 | $0.00 Strike: $26.05 | $0.00 |
DisclosureSEC source: 0000899243-20-024953 · doc4.xml · derivative · entry 6 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 45,351 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 11:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,397 | $149.30 | $357,872.10 |
DisclosureSEC source: 0000899243-20-024953 · doc4.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,327 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F5 · price: $149.30 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.18 to $149.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 11:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 26,966 | $148.56 | $4,006,068.96 |
DisclosureSEC source: 0000899243-20-024953 · doc4.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,724 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F4 · price: $148.56 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.17 to $149.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 11:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 11,132 | $147.68 | $1,643,973.76 |
DisclosureSEC source: 0000899243-20-024953 · doc4.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,690 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F3 · price: $147.68 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.17 to $148.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 11:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,856 | $146.85 | $713,103.60 |
DisclosureSEC source: 0000899243-20-024953 · doc4.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,822 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 11, 2020. F2 · price: $146.85 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.16 to $147.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 11:43 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 45,351 | $26.05 | $1,181,393.55 |
DisclosureSEC source: 0000899243-20-024953 · doc4.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.